Oncogenic CMTM6 drives M2a macrophages formation and fuels cervical cancer progression
These findings highlight exosomal CMTM6 as a crucial driver of immune suppression in CC, with the CMTM6/CD206/CCL2 axis significantly increasing the risk for CC patients. Our study underscores the potential of exosomal CMTM6 as both a prognostic biomarker and a therapeutic target for CC immunotherapy.
Authors
- Jianyi Ding
- Huijuan Zhou (ORCID: https://orcid.org/0000-0001-5358-8010)
- Xianghuo He (ORCID: https://orcid.org/0000-0001-8872-668X)
- Huang Baoyou
- Ting Huang (ORCID: https://orcid.org/0000-0001-7540-274X)
- Bo Yin (ORCID: https://orcid.org/0000-0001-9966-5835)
- Chun Chen (ORCID: https://orcid.org/0000-0002-7451-0519)
- Lingfei Han (ORCID: https://orcid.org/0000-0003-1914-0436)
- Yuan Lu (ORCID: https://orcid.org/0000-0002-9103-5211)
- Haoran Hu (ORCID: https://orcid.org/0000-0001-7923-5133)
- Yashi Zhu
Institutions
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Shanghai Tenth People's Hospital (CN)
- Obstetrics and Gynecology Hospital of Fudan University (CN)
- Shuguang Hospital (CN)
- Shanghai First Maternity and Infant Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-07-21
- DOI
- https://doi.org/10.3389/fimmu.2025.1621816
- Citations
- 4
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 3.19
Funders
- National Natural Science Foundation of China